CoChat
Sign Up
Cited by 54Endometriosis Research and TreatmentReproductive Health and ContraceptionEctopic Pregnancy Diagnosis and Management

Treatment of pelvic endometriosis with etonogestrel subdermal implant (Implanon®)

Open access
Yisa, Solomon B, Okenwa, Angela A, Husemeyer, Roy P·2005·Journal of Family Planning and Reproductive Health Care
DOI 10.1783/0000000052972799
Open this paper in CoChat — free accountOpen PDF

Abstract

Backgound: Endometriosis is one of the commonest benign gynaecological disorders and has a peak incidence between 30 and 45 years of age. Treatment options are medical or surgical, depending on the location and extent of the disease and the woman's childbearing aspirations or need for contraception. Over the past five decades several formulations of progestogen have been used to treat endometriosis. Methods: Our study was not planned research but a series of case studies of women with severe symptoms of endometriosis treated in an innovative way with a new long-acting progestogen contraceptive system (etonogestrel subdermal implant) which could reasonably have been expected to have a favourable effect on their disease and its symptoms. Results: Five women with severe pelvic endometriosis were treated. Two of them were nulliparous and wished to become pregnant in due course; the other three had completed their childbearing and were contemplating hysterectomy. One of the five women had relief of pelvic pain but requested removal of the implant after 3 months because of side effects; the other four remained very satisfied with their treatment for the symptoms of pelvic endometriosis. Two of the four very satisfied women have had their implant replaced and the other two are expected to have their implant replaced when necessary. Conclusion: Etonogestrel subdermal implants are an additional treatment option in women with symptoms related to pelvic endometriosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1783/0000000052972799

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The etonogestrel-releasing subdermal implant (ENG-implant) is effective in decreasing dyspareunia, dysmenorrhea, and nonmenstrual pelvic pain in women with endometriosis.

    “Few data are available also on the use of the etonogestrel-releasing subdermal implant (ENG- implant) for the treatment of women with endometriosis, resulting effective in decreasing dyspareunia, dysmenorrhea and nonmenstrual pelvic pain [239, 240].”

    From Hormonal treatments for endometriosis: The endocrine background (2022) · cites this paper as [240]

    Case 1 (page not supplied) reports substantially less severe dysmenorrhoea and no pelvic pain after implant insertion; the Results also report pelvic-pain relief in a five-woman case series. Case 1 says the woman did not experience dyspareunia after insertion, but does not establish that she had dyspareunia beforehand, so a decrease in that symptom is not demonstrated. The Discussion describes the cases as anecdotal rather than planned research. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

  • Few data are available on the use of the ENG implant for treatment of endometriosis, and the majority came from case reports and case series.

    “Few data are available on the use of this device for the treatment of endometriosis and the majority came from case reports and case series [93-95].”

    From Oral and depot progestin therapy for endometriosis: towards a personalized medicine (2017) · cites this paper as [94]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 2

  1. [2]2. Meyer R. Uber den Staude der Frage der Adenomyosites Adenomyoma in Allgemeinen und Insbesondere uber Adenomyosites seroepitheliolis Adenomyometitis Sarcomatosa. Zentralbl Gynakol 1919; 36: 745-759.
  2. [5]5. Lindsay PC. Medical and endocrine modulatory treatments. In: Shaw RW (ed.), Endometriosis. Oxford, UK: Blackwell Science, 1994; 193-195.

Cited by

Sorted by citations

Related

Authors
Yisa, S. B., Okenwa, A. A., & Husemeyer, R. P.
Affiliations
  • Leicester Royal Infirmary (GB)
  • Lincoln County Hospital (GB)
Corresponding author
Husemeyer, Roy P
Venue
Journal of Family Planning and Reproductive Health Care
Publisher
BMJ
Published
2005-01
Volume
31
Issue
1
Pages
67-70
ISSN
  • 1471-1893 (ISSN-L)
  • 2045-2098
DOI
10.1783/0000000052972799
OpenAlex
W1978196069
Cited by
54
References
13
Citations by year
2026: 1 · 2025: 2 · 2024: 4 · 2023: 2 · 2022: 3 · 2021: 4 · 2020: 2 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 3 · 2014: 3 · 2013: 3 · 2012: 3
FWCI
2.11
Type
journal article
Language
en
Open access
Locations
  • Journal of Family Planning and Reproductive Health Care (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ectopic Pregnancy Diagnosis and Management
Keywords
pelvic endometriosis, etonogestrel, subdermal contraceptive implant, Implanon, endometriosis treatment, pelvic pain, implant replacement, fertility preservation
MeSH terms
Adult, Contraceptives, Oral, Synthetic, Drug Implants, Endometriosis, Female, Humans, Middle Aged, Pelvis, Desogestrel

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review